In this study, matrix type patch formulations of flurbiprofen using certain skin permeation
enhancers [isopropyl myristate (IPM), isopropyl palmitate (IPP) and Tween 80] were formulated, evaluated
and compared. The cumulative amounts permeated and the permeation rates were higher for the prepared
formulations as compared to the controls (without enhancers). The results also revealed better skin
permeation characteristics of flurbiprofen using IPM than other enhancers. The pharmacokinetic parameters
of the optimized formulation (F7), calculated from the blood levels of the drug, revealed a profile
with the ability to maintain adequate plasma levels for 24 h (i.e. up to the next application): AUC(0-24)
10.406 ± 1.34ng.h/ml, Tmax 1.5 ± 0.91 and Cmax 1.3049 ± 0.21 µg.ml-1-. The amount of drug bioavailable for
targeting the site of action is comparable to that of market control. Based on experimental results, preparation
of 10 % flurbiprofen matrix type patch formulation containing IPM is promising